VIDEO: Monoclonal antibody shows promise in CDI treatment
SAN DIEGO — Mark H. Wilcox, MD, FRCPath, professor of medical microbiology at Leeds Teaching Hospitals and the University of Leeds, discusses findings from the MODIFY trials, which evaluated the safety and efficacy of monoclonal antibodies bezlotoxumab and actoxumab as adjunctive therapy for recurrent Clostridium difficile infection.
Results from the two phase 3 studies indicate that bezlotoxumab, which neutralizes C. difficile toxin B, significantly reduces the rate of recurrent C. difficile when taken in combination with antibiotics. Notably, actoxumab, which targets the A toxin, offered no additional benefit when administered alongside bezlotoxumab, suggesting that the neutralization of toxin B is sufficient to prevent recurrent disease.
Disclosure: Wilcox reports financial relationships with several pharmaceutical companies.